A solitary positive prostate cancer biopsy does not predict a unilateral lesion in radical prostatectomy specimens

References

• Yoon GS, Wang W, Osunkoya AO, Lane Z, Partin AW, Epstein JI. Residual tumor potentially left behind after local ablation therapy in prostate adenocarcinoma. J Urol 2008;179:2203–6.
   PubMedGoogle Scholar
• Gallina A, Chun FK, Suardi N, Eastham JA, Perrotte P, Graefen M, et al. Comparison of stage migration patterns between Europe and the USA: an analysis of 11,350 men treated with radical prostatectomy for prostate cancer. BJU Int 2008;101:1513–18.
   PubMed Web of Science ®Google Scholar
• Dong F, Reuther AM, Magi-Galluzzi C, Zhou M, Kupelian PA, Klein EA. Pathologic stage migration has slowed in the late PSA era. Urology 2007;70:839–42.
   Google Scholar
• Scales CDJr, Presti JCJr, Kane CJ, Terris MK, Aronson WJ, Amling CL, et al. Predicting unilateral prostate cancer based on biopsy features: implication for focal ablative therapy – results from the SEARCH database. J Urol 2007;178:1249–52.
   PubMed Web of Science ®Google Scholar
• Karavitakis M, Ahmed HU, Abel PD, Livni N, Hazell S, Winkler MH. Trends in pathologic outcomes after introduction of active surveillance in the UK: implication for focal therapy. Prostate 2012;72:1464–8.
   Google Scholar
• Bastacky SI, Wojno KJ, Walsh PC, Carmichael MJ, Epstein JI. Pathological features of hereditary prostate cancer. J Urol 1995;153:987–92.
   Google Scholar
• American Joint Committee on Cancer (AJC). Prostate. In Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. AJCC cancer staging manual. 7th ed. New York: Springer; 2010. p 457–68.
   Google Scholar
• Epstein JI, Allsbrook WCJr, Amin MB, Egevad LL. The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 2005;29:1228–42.
   PubMed Web of Science ®Google Scholar
• Koie T, Yamamoto H, Hatakeyama S, Kudoh S, Yoneyama T, Hashimoto Y, et al. Minimum incision endoscopic radical prostatectomy: clinical and oncological outcomes at a single institute. Eur J Surg Oncol 2011;37:805–10.
   Google Scholar
• Chen ME, Johnston D, Reyes AO, Soto CP, Babaian RJ, Troncoso P. A streamlined three-dimensional volume estimation method accurately classifies prostate tumors by volume. Am J Surg Pathol 2003;27:1291–301.
   PubMed Web of Science ®Google Scholar
• van Oort IM, Kok DE, Kiemeney LA, Hulsbergen-van de Kaa CA, Witjes JA. A single institution experience with biochemical recurrence after radical prostatectomy for tumors that on pathology are of small volume or “insignificant”. Urol Oncol 2009;27:509–13.
   Google Scholar
• Hong SK, Han BK, Chung JS, Park DS, Jeong SJ, Byun SS, et al. Evaluation of pT2 subdivisions in the TNM staging system for prostate cancer. BJU Int 2008;102:1214–18.
   Google Scholar
• Miller DC, Gruber SB, Hollenbeck BK, Montie JE, Wei JT. Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst 2006;98:1134–41.
   PubMedGoogle Scholar
• van den Bergh RC, Roemeling S, Roobol MJ, Roobol W, Schröder FH, Bangma CH. Prospective validation of active surveillance in prostate cancer: the PRIAS study. Eur Urol 2007;52:1560–3.
   PubMed Web of Science ®Google Scholar
• Carter HB, Kettermann A, Warlick C, Metter EJ, Landis P, Walsh PC, et al. Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol 2007;178:2359–65.
   PubMedGoogle Scholar
• Kakehi Y, Kamoto T, Shiraishi T, Ogawa O, Suzukamo Y, Fukuhara S, et al. Prospective evaluation of selection criteria for active surveillance in Japanese patients with stage T1cN0M0 prostate cancer. Jpn J Clin Oncol 2008;38:122–8.
   Google Scholar
• Ahmed HU, Pendse D, Illing R, Allen C, van der Meulen JH, Emberton M. Will focal therapy become a standard of care for men with localized prostate cancer? Nat Clin Pract Oncol 2007;4:632–42.
   PubMedGoogle Scholar
• Marien A, Gill I, Ukimura O, Nacim B, Villers A. Target ablation-image-guided therapy in prostate cancer. Urol Oncol 2014;32:912–23.
   PubMed Web of Science ®Google Scholar
• Lecornet E, Ahmed HU, Moore CM, Emberton M. Conceptual basis for focal therapy in prostate cancer. J Endourol 2010;24:811–18.
   Google Scholar
• van den Bos W, Muller BG, Ahmed H, Bangma CH, Barret E, Crouzet S, et al. Focal therapy in prostate cancer: international multidisciplinary consensus on trial design. Eur Urol 2014;65:1078–83.
   PubMed Web of Science ®Google Scholar
• Isbarn H, Karakiewics PI, Vogel S, Jelders C, Lughezzani G, Briganti A, et al. Unilateral prostate cancer cannot be accurately predict in low-risk patients. Int J Radiat Oncol Biol Phys 2010;77:784–7.
   PubMedGoogle Scholar
• Gallina A, Maccagnano C, Suardi N, Capitanio U, Abdollah F, Raber M, et al. Unilateral positive biopsies in low risk prostate cancer patients diagnosed with extended transrectal ultrasound-guided biopsy schemes do not predict unilateral prostate cancer at radical prostatectomy. BJU Int 2012;110:E64–8.
   Google Scholar
• Muezzinoglu A, Frolov M, Ohori M, Scardina PT, Ayala G. Clinicopathological significance of multifocal prostate cancer. Abstracts of annual meeting of USCAP. Mod Pathol 2006;19:151A.
   Google Scholar
• Eggener SE, Scardino PT, Carroll PR, Zelefsky MJ, Sartor O, Hricak H, et al. Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. J Urol 2007;178:2260–7.
   PubMed Web of Science ®Google Scholar
• Mitsuzuka K, Narita S, Koie T, Kaiho Y, Tsuchiya N, Yoneyama T, et al. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: active surveillance criteria. BJU Int 2013;111:914–20.
   Google Scholar
• Wolters T, Roobol MJ, van Leeuwen PJ, van der Bergh RCN, Hoedemaeker RF, van Leenders GJLH, et al. A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial. J Urol 2011;185:121–5.
   PubMed Web of Science ®Google Scholar
• Hashimoto Y, Okamoto A, Imai A, Yoneyama T, Hatakeyama S, Yoneyama T, et al. Biochemical outcome of small-volume or insignificant prostate cancer treated with radical prostatectomy in Japanese population. Int J Clin Oncol 2012;17:119–23.
   Google Scholar
• Arora R, Koch MO, Eble JN, Ulbright TM, Li L, Cheng L. Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate. Cancer 2004;100:2362–6.
   PubMed Web of Science ®Google Scholar